AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34135954 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) injection
Number of subjects: 124
Study 34135954 — intervention group
Group type: COMPARATOR
Intervention: Steroid injection
Number of subjects: 124
Study 32222360 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional EQUIPPED with in-person academic detailing coupled with audit and feedback
Number of subjects: 2
Study 32222360 — intervention group
Group type: COMPARATOR
Intervention: EQUIPPED dashboard with passive audit and feedback
Number of subjects: 2
Study 32976205 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 2 μg/kg
Number of subjects: 156
Study 32976205 — intervention group
Group type: COMPARATOR
Intervention: Oral midazolam 0.5 mg/kg
Number of subjects: 156
Study 32976205 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (placebo)
Number of subjects: 156
Study 37045502 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic-guided P2Y12 inhibitor therapy (ticagrelor for LOF carriers, clopidogrel for noncarriers)
Number of subjects: 5302
Study 37045502 — intervention group
Group type: COMPARATOR
Intervention: Conventional clopidogrel therapy
Number of subjects: 5302
Study 34298402 — intervention group
Group type: COMPARATOR
Intervention: DPCP alone (Group D)
Number of subjects: 50
Study 34298402 — intervention group
Group type: EXPERIMENTAL
Intervention: DPCP combined with anthralin (Group D/A)
Number of subjects: 50
Study 35536410 — intervention group
Group type: EXPERIMENTAL
Intervention: Active video games (AVGs) using Xbox‐Kinect‐360 device for 40 min/day, 3 days/week for 8 weeks plus airway clearance techniques (ACT)
Number of subjects: 32
Study 35536410 — intervention group
Group type: COMPARATOR
Intervention: Control group applied ACT only
Number of subjects: 32
Study 33850089 — intervention group
Group type: EXPERIMENTAL
Intervention: Noisy GVS
Number of subjects: 24
Study 33850089 — intervention group
Group type: COMPARATOR
Intervention: Conventional GVS
Number of subjects: 24
Study 32576229 — intervention group
Group type: EXPERIMENTAL
Intervention: galcanezumab 120 mg
Number of subjects: 2886
Study 32576229 — intervention group
Group type: EXPERIMENTAL
Intervention: galcanezumab 240 mg
Number of subjects: 2886
Study 32576229 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2886
Study 35400290 — intervention group
Group type: EXPERIMENTAL
Intervention: triceps surae PNF + PSA
Number of subjects: 16
Study 35400290 — intervention group
Group type: EXPERIMENTAL
Intervention: quadriceps PNF + PSA
Number of subjects: 16
Study 35596193 — intervention group
Group type: COMPARATOR
Intervention: Talking Control (TC) sessions
Number of subjects: 5
Study 34420531 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal mid-upper arm circumference (MUAC)
Number of subjects: 2831
Study 34420531 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal BMI
Number of subjects: 2831
Study 34420531 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary diversity
Number of subjects: 2831
Study 34420531 — intervention group
Group type: EXPERIMENTAL
Intervention: Meals per day
Number of subjects: 2831
Study 34420531 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating down and food aversion in pregnancy
Number of subjects: 2831
Study 34420531 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal z-scores of length-for-age (LAZ)
Number of subjects: 2831
Study 34420531 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal z-scores of weight-for-age (WAZ)
Number of subjects: 2831
Study 34420531 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal z-scores of weight-for-length (WLZ)
Number of subjects: 2831
Study 34420531 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal head circumference-for-age (HCAZ)
Number of subjects: 2831
Study 34536258 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acustimulation (TEA)
Number of subjects: 42
Study 34536258 — intervention group
Group type: COMPARATOR
Intervention: Sham-TEA
Number of subjects: 42
Study 32005781 — intervention group
Group type: EXPERIMENTAL
Intervention: arthroscopic tenotomy of the long head of the biceps tendon
Number of subjects: 172
Study 36328211 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling intervention (one-month counselling once-a-year for 3 years)
Number of subjects: 0
Study 36328211 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study 36328211 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling intervention
Number of subjects: 0
Study 32156136 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 0
Study 32156136 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 0
Study 35381849 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium yeast (200 µg/day) and coenzyme Q10 (200 mg/day)
Number of subjects: 443
Study 35381849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 443
Study 33840387 — intervention group
Group type: EXPERIMENTAL
Intervention: TURP or Thulium vapoenucleation (ThuP)
Number of subjects: 2363
Study 32497605 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen supplementation (10 L/min) for long durations (≥75th percentile)
Number of subjects: 99
Study 32497605 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen supplementation (10 L/min) for short durations (<75th percentile)
Number of subjects: 99
Study 32497605 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 99
Study 35605429 — intervention group
Group type: EXPERIMENTAL
Intervention: PRI-724 (280 mg/m2/4 h) administered intravenously twice weekly for 12 weeks
Number of subjects: 27
Study 33631372 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Reserve EnhAncement ThErapy (CREATE)
Number of subjects: 173
Study 33631372 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive approach
Number of subjects: 173
Study 33631372 — intervention group
Group type: COMPARATOR
Intervention: Community comparison group (CC)
Number of subjects: 173
Study 35674667 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-poor sanitation subsidy program
Number of subjects: 109
Study 35674667 — intervention group
Group type: COMPARATOR
Intervention: Control (no subsidy)
Number of subjects: 109
Study 32472357 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan 10 mg (generic product)
Number of subjects: 26
Study 32472357 — intervention group
Group type: COMPARATOR
Intervention: Volibris® (ambrisentan) 10 mg (reference product)
Number of subjects: 26
Study 32472357 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Ambrisentan 10 mg and Volibris® 10 mg)
Number of subjects: 26
Study 35172440 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Number of subjects: 200
Study 35172440 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid
Number of subjects: 200
Study 34363764 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 mL of 0.5% bupivacaine hydrochloride + 1 mL/4 mg dexamethasone (Group A1)
Number of subjects: 68
Study 34363764 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine hydrochloride + 1 mL/4 mg dexamethasone (Group B1)
Number of subjects: 68
Study 34363764 — intervention group
Group type: COMPARATOR
Intervention: 1.8 mL of 0.5% bupivacaine hydrochloride (Group A)
Number of subjects: 68
Study 34363764 — intervention group
Group type: COMPARATOR
Intervention: 0.75% ropivacaine hydrochloride (Group B)
Number of subjects: 68
Study 34011358 — intervention group
Group type: EXPERIMENTAL
Intervention: Artefenomel (800 mg) plus ferroquine (400 mg to 1200 mg)
Number of subjects: 373
Study 32764077 — intervention group
Group type: EXPERIMENTAL
Intervention: Trough-coupled tACS
Number of subjects: 24
Study 32764077 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplitude-modulated tACS
Number of subjects: 24
Study 32764077 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak-coupled tACS
Number of subjects: 24
Study 32764077 — intervention group
Group type: COMPARATOR
Intervention: Control tACS (80-Hz tACS continuously superimposed over 4-Hz tACS)
Number of subjects: 24
Study 35510765 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysteamine 5% cream
Number of subjects: 65
Study 35510765 — intervention group
Group type: COMPARATOR
Intervention: Hydroquinone 4%/ascorbic acid 3% cream (HC)
Number of subjects: 65
Study 34976662 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial support via telephone and e-mail (two phone calls and one e-mail over the first eight weeks)
Number of subjects: 356
Study 34976662 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (self-directed use)
Number of subjects: 356
Study 35303160 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill walking at 40% of age-predicted max heart rate (40HR)
Number of subjects: 30
Study 35303160 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill walking at 60% of age-predicted max heart rate (60HR)
Number of subjects: 30
Study 35303160 — intervention group
Group type: COMPARATOR
Intervention: Seated rest (NOEX)
Number of subjects: 30
Study 35303160 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (40HR, 60HR, NOEX)
Number of subjects: 30
Study 32106548 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized bilberry extract (SBE) 240 mg once daily for 12 weeks
Number of subjects: 109
Study 32106548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 34169518 — intervention group
Group type: EXPERIMENTAL
Intervention: Future as older adult thinking
Number of subjects: 144
Study 34169518 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 144
Study 32892297 — intervention group
Group type: EXPERIMENTAL
Intervention: Protect Your Family (PYF) behavioral intervention with male partners present
Number of subjects: 0
Study 32892297 — intervention group
Group type: COMPARATOR
Intervention: Control program with male partners present
Number of subjects: 0
Study 32892297 — intervention group
Group type: EXPERIMENTAL
Intervention: Protect Your Family (PYF) behavioral intervention without male partners present
Number of subjects: 0
Study 32892297 — intervention group
Group type: COMPARATOR
Intervention: Control program without male partners present
Number of subjects: 0
Study 33201232 — intervention group
Group type: EXPERIMENTAL
Intervention: α‐cyclodextrin
Number of subjects: 401
Study 33201232 — intervention group
Group type: EXPERIMENTAL
Intervention: hydrolyzed ginseng
Number of subjects: 401
Study 33201232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study 34002910 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) treatment
Number of subjects: 85
Study 34002910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 33377960 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscular tissue oxygen saturation‐guided care (n = 400)
Number of subjects: 800
Study 33377960 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 399)
Number of subjects: 800
Study 35039269 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingfei Huatan Huoxue Decoction combined with azithromycin
Number of subjects: 155
Study 35039269 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin (control group)
Number of subjects: 155
Study 32969605 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel risk score for predicting cardiovascular complications
Number of subjects: 1207
Study 34456324 — intervention group
Group type: EXPERIMENTAL
Intervention: Video training (n=121)
Number of subjects: 339
Study 34456324 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored, facilitator-led training (n=136)
Number of subjects: 339
Study 34456324 — intervention group
Group type: COMPARATOR
Intervention: Attention-placebo training focused on heat-related illness (n=82)
Number of subjects: 339
Study 34022835 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDS Fighter · Health Defense game-based intervention
Number of subjects: 0
Study 32422871 — intervention group
Group type: EXPERIMENTAL
Intervention: Campus forest therapy program
Number of subjects: 38
Study 32422871 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study 33993740 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruquintinib plus best supportive care
Number of subjects: 687
Study 33993740 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus best supportive care
Number of subjects: 687
Study 33130619 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of intervention for acute spinal cord injury (aSCI)
Number of subjects: 163
Study 33130619 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed diagnosis and intervention
Number of subjects: 163
Study 33130619 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaintiffs' awards in cases with disclosed amounts
Number of subjects: 163
Study 35059248 — intervention group
Group type: EXPERIMENTAL
Intervention: LMET + DPP4i treatment (low-dose metformin 750 mg/day + vildagliptin 100 mg/day)
Number of subjects: 20
Study 35059248 — intervention group
Group type: COMPARATOR
Intervention: HMET treatment (high-dose metformin 1500 mg/day)
Number of subjects: 20
Study 33842037 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Needling (DN)
Number of subjects: 11
Study 33842037 — intervention group
Group type: COMPARATOR
Intervention: Sham Dry Needling (SHAM)
Number of subjects: 11
Study 35103905 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally produced ready‐to‐use therapeutic food (L‐RUTF)
Number of subjects: 0
Study 35103905 — intervention group
Group type: COMPARATOR
Intervention: Standard ready‐to‐use therapeutic food (S‐RUTF)
Number of subjects: 0
Study 33389689 — intervention group
Group type: EXPERIMENTAL
Intervention: Molar incisor hypomineralisation (MIH)
Number of subjects: 1047
Study 33389689 — intervention group
Group type: COMPARATOR
Intervention: Health and demographic characteristics
Number of subjects: 1047
Study 35298865 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen matrix with deproteinized bovine bone mineral containing 10% collagen (DBBM-C)
Number of subjects: 30
Study 35298865 — intervention group
Group type: COMPARATOR
Intervention: Natural healing (control group)
Number of subjects: 30
Study 35183157 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance Body Tape (BBT) treatment for 3 weeks
Number of subjects: 26
Study 35183157 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 26
Study 35594559 — intervention group
Group type: EXPERIMENTAL
Intervention: Isatuximab plus carfilzomib and dexamethasone (Isa‐Kd)
Number of subjects: 302
Study 35594559 — intervention group
Group type: COMPARATOR
Intervention: Carfilzomib and dexamethasone (Kd)
Number of subjects: 302
Study 33080012 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 162
Study 33080012 — intervention group
Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 162
Study 33099278 — intervention group
Group type: EXPERIMENTAL
Intervention: VA-ECMO with LV unloading strategies
Number of subjects: 0
Study 33099278 — intervention group
Group type: COMPARATOR
Intervention: VA-ECMO without LV unloading strategies
Number of subjects: 0
Study 35684098 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation during a 12-week lifestyle program
Number of subjects: 44
Study 35684098 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle program without Vitamin D supplementation
Number of subjects: 44
Study 35684098 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight adolescents (control group)
Number of subjects: 44
Study 34839601 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate group
Number of subjects: 68
Study 34839601 — intervention group
Group type: COMPARATOR
Intervention: Heparin group
Number of subjects: 68
Study 33779320 — intervention group
Group type: EXPERIMENTAL
Intervention: AIM HI (An Individualized Mental Health Intervention for ASD)
Number of subjects: 0
Study 33779320 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 0
Study 33256758 — intervention group
Group type: EXPERIMENTAL
Intervention: Single screening and treatment (SST) strategy using malaria rapid diagnostic tests (RDT)
Number of subjects: 1845
Study 36094502 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (INT) - 1 day/week of nutrition and health education and 3 days/week of physical activity for 6 months.
Number of subjects: 117
Study 36094502 — intervention group
Group type: COMPARATOR
Intervention: Usual care control (UCC) - 2 visits with a pediatric endocrinologist and a bilingual, bicultural registered dietitian.
Number of subjects: 117
Study 36130753 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined low energy diet (800-900 kcal/day) with meal replacement products and supervised exercise training (aerobic and resistance) three times weekly during the intensive phase (12 weeks)
Number of subjects: 100
Study 36130753 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control arm)
Number of subjects: 100
Study 32345700 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist intervention targeting drug-related problems (DRPs), initiated within a week of discharge, involving medical chart reviews, phone interviews, and medication reviews.
Number of subjects: 700
Study 32345700 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control)
Number of subjects: 700
Study 34984964 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adult client in good health
Number of subjects: 488
Study 34984964 — intervention group
Group type: COMPARATOR
Intervention: Older adult client in poor health
Number of subjects: 488
Study 34984964 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ageist attitudes
Number of subjects: 488
Study 34984964 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher aging anxiety
Number of subjects: 488
Study 34682655 — intervention group
Group type: EXPERIMENTAL
Intervention: IMI psychosomatic aftercare
Number of subjects: 142
Study 34682655 — intervention group
Group type: COMPARATOR
Intervention: Face-to-Face (F2F) psychosomatic aftercare
Number of subjects: 142
Study 32414185 — intervention group
Group type: EXPERIMENTAL
Intervention: PMA-zeolite (Multizeo Med)
Number of subjects: 120
Study 32414185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 36409639 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin intravesical instillation
Number of subjects: 370
Study 36409639 — intervention group
Group type: COMPARATOR
Intervention: Sham instillation
Number of subjects: 370
Study 33238805 — intervention group
Group type: EXPERIMENTAL
Intervention: #ad
Number of subjects: 200
Study 33238805 — intervention group
Group type: COMPARATOR
Intervention: #sponsored
Number of subjects: 200
Study 33238805 — intervention group
Group type: EXPERIMENTAL
Intervention: #ad and #sponsored
Number of subjects: 200
Study 36001196 — intervention group
Group type: EXPERIMENTAL
Intervention: PEERS® intervention (hybrid mode)
Number of subjects: 29
Study 36001196 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control Group
Number of subjects: 29
Study 34384499 — intervention group
Group type: COMPARATOR
Intervention: Single oral dose of 240, 480, 960, or 1440 mg ES16001 (SAD study)
Number of subjects: 48
Study 34384499 — intervention group
Group type: COMPARATOR
Intervention: Once daily doses of 480 or 960 mg ES16001 for 5 days (MAD study)
Number of subjects: 48
Study 34384499 — intervention group
Group type: COMPARATOR
Intervention: Placebo (SAD and MAD studies)
Number of subjects: 48
Study 33522565 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized exercise program (2 daily sessions of 20 minutes for 5-7 days)
Number of subjects: 297
Study 33522565 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 297
Study 33392869 — intervention group
Group type: EXPERIMENTAL
Intervention: Subharmonic imaging (SHI) using Sonazoid contrast agent
Number of subjects: 131
Study 32090660 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback (NFB) treatment, 40 sessions targeting very slow cortical potential range, addressing inhibitory deficits through right and left prefrontal training.
Number of subjects: 20
Study 32090660 — intervention group
Group type: COMPARATOR
Intervention: Control group (sham treatment).
Number of subjects: 20
Study 34389850 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster randomized trial design
Number of subjects: 0
Study 33523186 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat vegan diet
Number of subjects: 0
Study 33523186 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 35568668 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-Urethral Sling (MUS) surgery
Number of subjects: 259
Study 35568668 — intervention group
Group type: EXPERIMENTAL
Intervention: Peri-urethral bulking injections (PBI) with polydimethylsiloxane Urolastic (PDMS-U)
Number of subjects: 259
Study 35568668 — intervention group
Group type: COMPARATOR
Intervention: Both MUS and PBI
Number of subjects: 259
Study 33740415 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive hydration plus rectal NSAIDs (100 mg diclofenac or indomethacin); aggressive hydration comprised 20 mL/kg intravenous Ringer's lactate solution within 60 min from the start of ERCP, followed by 3 mL/kg per h for 8 h.
Number of subjects: 826
Study 33740415 — intervention group
Group type: COMPARATOR
Intervention: Control group received rectal NSAIDs (100 mg diclofenac or indomethacin) alone with normal intravenous saline (maximum of 1·5 mL/kg per h and 3 L per 24 h).
Number of subjects: 826
Study 33740415 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive hydration plus rectal NSAIDs
Number of subjects: 826
Study 33740415 — intervention group
Group type: COMPARATOR
Intervention: Control group (rectal NSAIDs alone)
Number of subjects: 826
Study 36048234 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic capsular release (ACR)
Number of subjects: 85
Study 36048234 — intervention group
Group type: COMPARATOR
Intervention: Manipulation under anaesthesia (MUA)
Number of subjects: 85
Study 32584199 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 infection in children
Number of subjects: 0
Study 32584199 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystem inflammatory syndrome in children (MIS-C)
Number of subjects: 0
Study 32584199 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical trials for therapeutics and vaccine development
Number of subjects: 0
Study 32584199 — intervention group
Group type: EXPERIMENTAL
Intervention: Pandemic control measures
Number of subjects: 0